肥胖和心房:从机制到治疗
Jenelle K Dziano1, Jonathan P Ariyaratnam2, Melissa E Middeldorp3
1Centre for Heart Rhythm Disorders, The University of Adelaide, Royal Adelaide Hospital and South Australian Health & Medical Research Institute, Adelaide, SA, Australia. Electronic address: https://x.com/JenelleDziano.
Heart, lung & circulation
|September 4, 2025
概括
肥胖会通过各种生物机制显著增加患心房的风险. 减肥策略对于治疗肌痛关节炎和预防其日益蔓延至关重要.
科学领域:
- 心脏病学
- 代谢疾病
- 公共卫生
背景情况:
- 全球肥胖率正在上升,预计到2050年将有38亿人受到影响.
- 随着肥胖流行,心房动的发病率和患病率也在上升.
- 肥胖与心肌关联,例如左心房重塑,心上脂肪,炎症和并发症.
研究的目的:
- 审查与肥胖相关的证据作为心房动 (AF) 的重要危险因素.
- 讨论目前和新兴的治疗方法,以治疗肥胖症.
- 探讨预防社区中肌痛风险增加的策略.
主要方法:
- 对现有科学证据的文献审查.
- 通过肥胖影响AF发展的途径分析.
- 检查伴随性疾病 (高血压,糖尿病,睡眠呼吸暂停) 在AF中的作用.
- 评估减肥作为AF复发的治疗干预措施
主要成果:
- 肥胖通过左心房重塑,心上脂肪组织,心脏负荷变化,炎症和RAAS激活导致AF.
- 体重减轻已被确定为减少症状性肌前膜复发的一个关键因素.
- 药物治疗肥胖症提供了新的途径来改善AF患者的护理.
结论:
- 肥胖是心房的主要可改变的风险因素.
- 综合管理肥胖及其伴随性疾病对于AF的预防和治疗至关重要.
- 新兴的肥胖药物疗法有望改善AF的结果.
相关概念视频
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Obesity
609
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
609
Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
Dysrhythmias VI: Management of Dysrhythmias
106
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
106
Aortic Regurgitation III: Medical Management
39
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
39
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27


